Medpace Holdings, Inc. (MEDP) stock

MEDPNasdaqServices-Commercial Physical & Biological ResearchFiscal year ends December 31

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Oct 22, 2026Score 15/3051% above fair value

$652.01−25.55 (-3.77%)

Close on Oct 30, 2026Market cap $18.20BP/E 38.2Yield –

Earnings

Medpace's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report

Feb 8, 2027

Q4 FY2026 · estimated, after the close

Revenue, Q3 FY2026

$716.00M

+8.5% on a year earlier

EPS, Q3 FY2026

$4.84

$3.86 a year earlier

Latest guidance

Issued

Oct 21, 2026 · 4 items

Quarterly results

Revenue and earnings per share from each of Medpace's earnings releases, newest first

Quarter	Reported	Revenue	YoY	EPS	Source
Q4 FY2026ended Dec 31, 2026	Feb 8, 2027Expected	–	–	–	–
Q3 FY2026ended Sep 30, 2026	Oct 21, 2026after the close	$716.00M	+8.5%	$4.84	Release
Q2 FY2026ended Jun 30, 2026	Jul 22, 2026after the close	$707.30M	+17.2%	$4.25	Release
Q1 FY2026ended Mar 31, 2026	Apr 22, 2026after the close	$706.60M	+26.5%	$4.28	Release
Q4 FY2025ended Dec 31, 2025	Feb 9, 2026after the close	$708.50M	+32.0%	$4.67	Release
Q3 FY2025ended Sep 30, 2025	Oct 22, 2025after the close	$659.90M	+23.7%	$3.86	Release
Q2 FY2025ended Jun 30, 2025	Jul 21, 2025after the close	$603.30M	+14.2%	$3.10	Release
Q1 FY2025ended Mar 31, 2025	Apr 21, 2025after the close	$558.60M	+9.3%	$3.67	Release
Q4 FY2024ended Dec 31, 2024	Feb 10, 2025after the close	$536.60M	+7.7%	$3.67	Release
Q3 FY2024ended Sep 30, 2024	Oct 21, 2024after the close	$533.30M	+8.3%	$3.01	Release
Q2 FY2024ended Jun 30, 2024	Jul 22, 2024after the close	$528.10M	+14.6%	$2.75	Release
Q1 FY2024ended Mar 31, 2024	Apr 22, 2024after the close	$511.00M	+17.7%	$3.20	Release
Q4 FY2023ended Dec 31, 2023	Feb 12, 2024after the close	$498.40M	+26.5%	$2.46	Release
Q3 FY2023ended Sep 30, 2023	Oct 23, 2023after the close	$492.50M	+28.4%	$2.22	Release
Q2 FY2023ended Jun 30, 2023	Jul 24, 2023after the close	$460.90M	+31.2%	$1.93	Release
Q1 FY2023ended Mar 31, 2023	Apr 24, 2023after the close	$434.10M	+31.2%	$2.27	Release
Q4 FY2022ended Dec 31, 2022	Feb 13, 2023after the close	$394.10M	+27.7%	$2.12	Release
Q3 FY2022ended Sep 30, 2022	Oct 24, 2022after the close	$383.70M	+29.8%	$2.05	Release
Q2 FY2022ended Jun 30, 2022	Jul 25, 2022after the close	$351.20M	–	$1.46	Release
Q1 FY2022ended Mar 31, 2022	Apr 25, 2022after the close	$330.90M	–	$1.69	Release
Q4 FY2021ended Dec 31, 2021	Feb 14, 2022after the close	$308.60M	–	$1.32	Release
Q3 FY2021ended Sep 30, 2021	Oct 25, 2021after the close	$295.60M	–	$1.29	Release
Q2 FY2021ended Jun 30, 2021	Jul 26, 2021after the close	–	–	–	Filing
Q1 FY2021ended Mar 31, 2021	Apr 26, 2021after the close	–	–	–	Filing
Q4 FY2020ended Dec 31, 2020	Feb 16, 2021before the open	–	–	–	Filing
Q3 FY2020ended Sep 30, 2020	Oct 26, 2020after the close	–	–	–	Filing

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Current guidance

Medpace's latest outlook for periods it has not reported yet, compared with what it said before

Metric	Period	Guidance	Before	Change	Given
growth	FY2026	+8.9% – +12.8%	–	New	Apr 22, 2026
revenue	FY2026	$2.84B – $2.86B	–	New	Oct 21, 2026
revenueGAAP	FY2026	$2.81B – $2.89B	–	New	Jul 22, 2026
revenue	FY2026	$2.76B – $2.86B	$2.76B – $2.86B	Reaffirmed	Apr 22, 2026
EBITDAnon-GAAP	FY2026	$638.00M – $652.00M	–	New	Oct 21, 2026
EBITDAnon-GAAP	FY2026	$618.00M – $642.00M	$605.00M – $635.00M	Raised	Jul 22, 2026
diluted earnings per share (GAAP)GAAP	FY2026	$17.97 – $18.32	–	New	Oct 21, 2026
diluted earnings per share (GAAP)GAAP	FY2026	$17.25 – $17.95	$16.68 – $17.50	Raised	Jul 22, 2026
diluted weighted average shares outstanding	FY2026	28.6	29.2	Lowered	Jul 22, 2026
GAAP net incomeGAAP	FY2026	$514.00M – $524.00M	–	New	Oct 21, 2026
GAAP net incomeGAAP	FY2026	$494.00M – $514.00M	$487.00M – $511.00M	Raised	Jul 22, 2026
interest income	FY2026	$21.10M	$27.50M	Lowered	Jul 22, 2026
tax rate	FY2026	19% – 19.5%	19% – 20%	Lowered	Jul 22, 2026

Guidance vs results

The last range Medpace gave before each report, against the figure it then reported. Full years add up the four quarters.

Period	Metric	Guidance	Actual	Result
FY2025	EPS (GAAP)	$14.60 – $14.86	$15.30Σ4Q	Above range
FY2025	Revenue	$2.48B – $2.53B	$2.53BΣ4Q	Within range
FY2025	Revenue growth	+17.6% – +20%	+19.98%Σ4Q	Within range

Guidance history

Every forecast Medpace put in an earnings release, newest first

Given	Metric	Period	Guidance	Change
Oct 21, 2026	EBITDA	FY2026	$638.00M – $652.00M	New
Oct 21, 2026	diluted earnings per share (GAAP)	FY2026	$17.97 – $18.32	New
Oct 21, 2026	GAAP net income	FY2026	$514.00M – $524.00M	New
Oct 21, 2026	revenue	FY2026	$2.84B – $2.86B	New
Jul 22, 2026	EBITDA	FY2026	$618.00M – $642.00M	Raised
Jul 22, 2026	diluted earnings per share (GAAP)	FY2026	$17.25 – $17.95	Raised
Jul 22, 2026	diluted weighted average shares outstanding	FY2026	28.6	Lowered
Jul 22, 2026	tax rate	FY2026	19% – 19.5%	Lowered
Jul 22, 2026	interest income	FY2026	$21.10M	Lowered
Jul 22, 2026	GAAP net income	FY2026	$494.00M – $514.00M	Raised
Jul 22, 2026	revenue	FY2026	$2.81B – $2.89B	New
Apr 22, 2026	EBITDA	FY2026	$605.00M – $635.00M	Reaffirmed
Apr 22, 2026	diluted earnings per share (GAAP)	FY2026	$16.68 – $17.50	Reaffirmed
Apr 22, 2026	diluted weighted average shares outstanding	FY2026	29.2	New
Apr 22, 2026	tax rate	FY2026	19% – 20%	New
Apr 22, 2026	interest income	FY2026	$27.50M	New
Apr 22, 2026	GAAP net income	FY2026	$487.00M – $511.00M	New
Apr 22, 2026	growth	FY2026	+8.9% – +12.8%	New
Apr 22, 2026	revenue	FY2026	$2.76B – $2.86B	Reaffirmed
Feb 9, 2026	EBITDA	FY2026	$605.00M – $635.00M	New
Feb 9, 2026	diluted earnings per share (GAAP)	FY2026	$16.68 – $17.50	New
Feb 9, 2026	revenue	FY2026	$2.76B – $2.86B	New
Oct 22, 2025	EBITDA	FY2025	$545.00M – $555.00M	Raised
Oct 22, 2025	diluted earnings per share (GAAP)	FY2025	$14.60 – $14.86	Raised
Oct 22, 2025	diluted weighted average shares outstanding	FY2025	29.5	Raised
Oct 22, 2025	tax rate	FY2025	18.25% – 18.75%	Lowered
Oct 22, 2025	interest income	FY2025	$12.20M	Raised
Oct 22, 2025	GAAP net income	FY2025	$431.00M – $439.00M	Raised
Oct 22, 2025	revenue growth	FY2025	+17.6% – +20%	New
Oct 22, 2025	revenue	FY2025	$2.48B – $2.53B	Raised
Jul 21, 2025	EBITDA	FY2025	$515.00M – $545.00M	New
Jul 21, 2025	diluted earnings per share (GAAP)	FY2025	$13.76 – $14.53	New
Jul 21, 2025	diluted weighted average shares outstanding	FY2025	29.4	New
Jul 21, 2025	tax rate	FY2025	18.5% – 19%	New
Jul 21, 2025	interest income	FY2025	$11.60M	New
Jul 21, 2025	GAAP net income	FY2025	$405.00M – $428.00M	New
Jul 21, 2025	revenue	FY2025	$2.42B – $2.52B	New
Apr 21, 2025	EBITDA	FY2025	$462.00M – $492.00M	Reaffirmed
Apr 21, 2025	diluted earnings per share (GAAP)	FY2025	$12.26 – $13.04	Raised
Apr 21, 2025	diluted shares outstanding	FY2025	30.8	Lowered
Apr 21, 2025	tax rate	FY2025	15.5% – 16.5%	Lowered
Apr 21, 2025	interest income	FY2025	$15.80M	Lowered
Apr 21, 2025	GAAP net income	FY2025	$378.00M – $402.00M	Reaffirmed
Apr 21, 2025	revenue growth	FY2025	+1.5% – +6.2%	Raised
Apr 21, 2025	revenue	FY2025	$2.14B – $2.24B	Raised
Feb 10, 2025	EBITDA	FY2025	$462.00M – $492.00M	New
Feb 10, 2025	diluted earnings per share (GAAP)	FY2025	$11.93 – $12.69	New
Feb 10, 2025	diluted shares outstanding	FY2025	31.7	New
Feb 10, 2025	tax rate	FY2025	18% – 19%	New
Feb 10, 2025	interest income	FY2025	$30.50M	New
Feb 10, 2025	GAAP net income	FY2025	$378.00M – $402.00M	New
Feb 10, 2025	growth	FY2025	0% – +4.8%	New
Feb 10, 2025	revenue	FY2025	$2.11B – $2.21B	New
Oct 21, 2024	EBITDA	FY2024	$450.00M – $470.00M	Raised
Oct 21, 2024	diluted earnings per share (GAAP)	FY2024	$11.71 – $12.09	Raised
Oct 21, 2024	diluted shares outstanding	FY2024	32.1	Reaffirmed
Oct 21, 2024	tax rate	FY2024	15.5% – 16.5%	Raised
Oct 21, 2024	interest income	FY2024	$24.40M	Raised
Oct 21, 2024	GAAP net income	FY2024	$376.00M – $388.00M	Raised
Oct 21, 2024	revenue growth	FY2024	+10.8% – +12.9%	New
Oct 21, 2024	revenue	FY2024	$2.09B – $2.13B	Lowered
Jul 22, 2024	EBITDA	FY2024	$430.00M – $460.00M	Raised
Jul 22, 2024	diluted earnings per share (GAAP)	FY2024	$11.24 – $11.93	Raised
Jul 22, 2024	diluted shares outstanding	FY2024	32.1	New
Jul 22, 2024	tax rate	FY2024	15% – 16%	Lowered
Jul 22, 2024	interest income	FY2024	$24.00M	New
Jul 22, 2024	GAAP net income	FY2024	$361.00M – $383.00M	Raised
Jul 22, 2024	revenue	FY2024	$2.13B – $2.18B	Lowered
Apr 22, 2024	EBITDA	FY2024	$415.00M – $445.00M	Raised
Apr 22, 2024	diluted earnings per share (GAAP)	FY2024	$10.79 – $11.47	Raised
Apr 22, 2024	GAAP net income	FY2024	$347.00M – $369.00M	Raised
Apr 22, 2024	revenue	FY2024	$2.15B – $2.20B	Reaffirmed
Feb 12, 2024	EBITDA	FY2024	$400.00M – $430.00M	Raised
Feb 12, 2024	diluted earnings per share (GAAP)	FY2024	$10.18 – $10.87	New
Feb 12, 2024	tax rate	FY2024	16% – 17%	New
Feb 12, 2024	GAAP net income	FY2024	$326.00M – $348.00M	New
Feb 12, 2024	revenue	FY2024	$2.15B – $2.20B	Reaffirmed
Oct 23, 2023	EBITDA	FY2023	$353.00M – $361.00M	Raised
Oct 23, 2023	EBITDA	FY2024	$390.00M – $415.00M	New
Oct 23, 2023	diluted earnings per share (GAAP)	FY2023	$8.54 – $8.66	Raised
Oct 23, 2023	tax rate	FY2023	16.25% – 17.25%	Lowered
Oct 23, 2023	GAAP net income	FY2023	$272.00M – $276.00M	Raised
Oct 23, 2023	revenue	FY2023	$1.87B – $1.89B	Raised
Oct 23, 2023	revenue	FY2024	$2.15B – $2.20B	New
Jul 24, 2023	EBITDA	FY2023	$340.00M – $358.00M	Raised
Jul 24, 2023	diluted earnings per share (GAAP)	FY2023	$8.04 – $8.50	Raised
Jul 24, 2023	tax rate	FY2023	17.5% – 18.5%	Reaffirmed
Jul 24, 2023	GAAP net income	FY2023	$256.00M – $271.00M	Raised
Jul 24, 2023	revenue	FY2023	$1.84B – $1.88B	Raised
Apr 24, 2023	EBITDA	FY2023	$335.00M – $355.00M	Raised
Apr 24, 2023	diluted earnings per share (GAAP)	FY2023	$7.81 – $8.40	Raised
Apr 24, 2023	tax rate	FY2023	17.5% – 18.5%	Reaffirmed
Apr 24, 2023	GAAP net income	FY2023	$250.00M – $269.00M	Raised
Apr 24, 2023	revenue	FY2023	$1.75B – $1.81B	Raised
Feb 13, 2023	EBITDA	FY2023	$325.00M – $350.00M	Reaffirmed
Feb 13, 2023	diluted earnings per share (GAAP)	FY2023	$7.53 – $8.14	New
Feb 13, 2023	tax rate	FY2023	17.5% – 18.5%	New
Feb 13, 2023	GAAP net income	FY2023	$245.00M – $265.00M	New
Feb 13, 2023	revenue	FY2023	$1.69B – $1.75B	Raised
Oct 24, 2022	EBITDA	FY2022	$302.00M – $310.00M	Raised
Oct 24, 2022	EBITDA	FY2023	$325.00M – $350.00M	New
Oct 24, 2022	diluted earnings per share (GAAP)	FY2022	$6.88 – $7.00	Raised
Oct 24, 2022	GAAP net income	FY2022	$232.00M – $236.00M	Raised
Oct 24, 2022	revenue	FY2022	$1.44B – $1.46B	Raised
Oct 24, 2022	revenue	FY2023	$1.68B – $1.74B	New
Jul 25, 2022	EBITDA	FY2022	$268.00M – $280.00M	Raised
Jul 25, 2022	diluted earnings per share (GAAP)	FY2022	$6.07 – $6.36	Raised
Jul 25, 2022	GAAP net income	FY2022	$205.00M – $215.00M	Narrowed
Jul 25, 2022	revenue	FY2022	$1.41B – $1.44B	Narrowed
Apr 25, 2022	EBITDA	FY2022	$262.00M – $278.00M	Reaffirmed
Apr 25, 2022	diluted earnings per share (GAAP)	FY2022	$5.72 – $6.06	Raised
Apr 25, 2022	fully diluted shares	FY2022	35.6	New
Apr 25, 2022	tax rate	FY2022	13.5% – 14.5%	Reaffirmed
Apr 25, 2022	GAAP net income	FY2022	$204.00M – $216.00M	Reaffirmed
Apr 25, 2022	revenue	FY2022	$1.40B – $1.46B	Reaffirmed
Feb 14, 2022	EBITDA	FY2022	$262.00M – $278.00M	Reaffirmed
Feb 14, 2022	diluted earnings per share (GAAP)	FY2022	$5.35 – $5.67	New
Feb 14, 2022	tax rate	FY2022	13.5% – 14.5%	New
Feb 14, 2022	GAAP net income	FY2022	$204.00M – $216.00M	New
Feb 14, 2022	revenue	FY2022	$1.40B – $1.46B	New
Oct 25, 2021	EBITDA	FY2021	$216.00M – $222.00M	New
Oct 25, 2021	EBITDA	FY2022	$262.00M – $278.00M	New
Oct 25, 2021	diluted earnings per share (GAAP)	FY2021	$4.66 – $4.77	New
Oct 25, 2021	tax rate	FY2021	9.5% – 10.5%	New
Oct 25, 2021	GAAP net income	FY2021	$176.00M – $180.00M	New
Oct 25, 2021	revenue	FY2021	$1.14B – $1.15B	New
Oct 25, 2021	revenue	FY2022	$1.40B – $1.46B	New

Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.